Seeking Alpha

Cell Therapeutics gets French approval for non-Hodgkin lymphoma drug

Cell Therapeutics (CTIC) has received market access from France's National Health Authority for the company's Pixuvri drug to treat patients with advanced B-cell non-Hodgkin lymphoma.

Pixuvri now needs to be approved for hospital use so that patients can receive reimbursement for the drug.

Shares fly 17.9%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs